{"id":1022,"date":"2026-05-07T04:28:24","date_gmt":"2026-05-07T04:28:24","guid":{"rendered":"https:\/\/ulemnrme.a2hosted.com\/wordpress\/?page_id=1022"},"modified":"2026-06-13T11:44:28","modified_gmt":"2026-06-13T18:44:28","slug":"study-4","status":"publish","type":"page","link":"https:\/\/diaendo.com\/index.php\/study-4\/","title":{"rendered":"Eloralintide + Tirzepatide (Study 4)"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row full_width=\u201dstretch_row\u201d css=\u201d.vc_custom_tt_hdr{background-color: #149d79 !important; padding-top: 28px !important; padding-bottom: 24px !important;}\u201d][vc_column][vc_custom_heading text=\u201dCurrently Recruiting  \u00b7  Clinical Research\u201d font_container=\u201dtag:p|font_size:11px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dEloralintide + Tirzepatide in Overweight & Obesity\u201d font_container=\u201dtag:h1|font_size:36px|text_align:left|color:%23ffffff|line_height:1.15\u2033 use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dA study of LY3841136 (eloralintide), a GIP receptor agonist, given together with tirzepatide in adults who are overweight or have obesity.\u201d font_container=\u201dtag:p|font_size:15px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][\/vc_column][\/vc_row][vc_row][vc_column width=\u201d1\/1\u2033][vc_column_text]<\/p>\n<p class=\"de-intro\">\u2190 <a href=\"\/clinical-research\/\">Back to Clinical Research<\/a>  \u00b7  Sponsor: Eli Lilly  \u00b7  Duration: up to 42 weeks  \u00b7  ClinicalTrials.gov: NCT06345066<\/p>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=\u201d1\/1\u2033][vc_column_text]<\/p>\n<p class=\"de-section\">About This Study<\/p>\n<p class=\"de-q\">What is being studied?<\/p>\n<div class=\"de-a\">This study evaluates <strong>LY3841136 (eloralintide)<\/strong> \u2014 an investigational GIP receptor agonist \u2014 given in combination with <strong>tirzepatide<\/strong> in adults who are overweight or living with obesity. The primary focus is safety and tolerability, with body-weight change and the drug\u2019s pharmacokinetics assessed as secondary measures.<\/div>\n<p class=\"de-q\">Why combine these agents?<\/p>\n<div class=\"de-a\">Tirzepatide is already a dual GIP\/GLP-1 receptor agonist. Adding eloralintide is intended to explore whether further engaging the GIP pathway can enhance weight-management outcomes. Because this is an early-phase study, careful safety monitoring is central to the design.<\/div>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=\u201d1\/1\u2033][vc_column_text]<\/p>\n<p class=\"de-section\">Eligibility Criteria<\/p>\n<p class=\"de-q\">Who can participate?<\/p>\n<div class=\"de-a\">Eligibility is confirmed at a screening visit. The summary below covers the main criteria; our research team reviews the full list with you.<\/div>\n<div class=\"de-card\"><strong>Key Inclusion Criteria<\/strong><br \/>\u2022 Adults age 18\u201365 years<br \/>\u2022 BMI 27\u201345 kg\/m\u00b2 (overweight or obese)<br \/>\u2022 Otherwise generally healthy<\/div>\n<div class=\"de-card\"><strong>Key Exclusion Criteria<\/strong><br \/>\u2022 Type 1 or type 2 diabetes<br \/>\u2022 Clinically significant ECG abnormality<br \/>\u2022 Participation in another clinical trial within the prior 30 days<\/div>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=\u201d1\/1\u2033][vc_column_text]<\/p>\n<p class=\"de-section\">What Participation Involves<\/p>\n<p class=\"de-q\">What can I expect?<\/p>\n<div class=\"de-a\">This is an early-phase study lasting up to 42 weeks. Participants receive tirzepatide together with the investigational agent and are followed closely with study visits that include safety assessments, body-weight measurements, and blood draws to characterize how the medication behaves in the body.<\/div>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=\u201d1\/1\u2033][vc_column_text]<\/p>\n<p class=\"de-section\">Interested?<\/p>\n<div class=\"de-callout\"><strong>Talk to our research team<\/strong><br \/>If you are overweight or living with obesity and would like to learn whether this study is a fit, contact our research team. We will review eligibility and what participation involves with you. Email <a href=\"mailto:research@endotrials.org\">research@endotrials.org<\/a> or call our office.<\/div>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row full_width=\u201dstretch_row\u201d css=\u201d.vc_custom_tt_hdr{background-color: #149d79 !important; padding-top: 28px !important; padding-bottom: 24px !important;}\u201d][vc_column][vc_custom_heading text=\u201dCurrently Recruiting \u00b7 Clinical Research\u201d font_container=\u201dtag:p|font_size:11px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dEloralintide + Tirzepatide in Overweight &#038; Obesity\u201d font_container=\u201dtag:h1|font_size:36px|text_align:left|color:%23ffffff|line_height:1.15\u2033 use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dA study of LY3841136 (eloralintide), a GIP receptor agonist, given together with tirzepatide in adults who are overweight or have obesity.\u201d font_container=\u201dtag:p|font_size:15px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][\/vc_column][\/vc_row][vc_row][vc_column width=\u201d1\/1\u2033][vc_column_text] \u2190 Back to Clinical&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_gspb_post_css":"","footnotes":""},"class_list":["post-1022","page","type-page","status-publish","hentry","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eloralintide + Tirzepatide (Study 4) - Diaendo<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eloralintide + Tirzepatide (Study 4) - Diaendo\" \/>\n<meta property=\"og:description\" content=\"[vc_row full_width=\u201dstretch_row\u201d css=\u201d.vc_custom_tt_hdr{background-color: #149d79 !important; padding-top: 28px !important; padding-bottom: 24px !important;}\u201d][vc_column][vc_custom_heading text=\u201dCurrently Recruiting \u00b7 Clinical Research\u201d font_container=\u201dtag:p|font_size:11px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dEloralintide + Tirzepatide in Overweight &amp; Obesity\u201d font_container=\u201dtag:h1|font_size:36px|text_align:left|color:%23ffffff|line_height:1.15\u2033 use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dA study of LY3841136 (eloralintide), a GIP receptor agonist, given together with tirzepatide in adults who are overweight or have obesity.\u201d font_container=\u201dtag:p|font_size:15px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][\/vc_column][\/vc_row][vc_row][vc_column width=\u201d1\/1\u2033][vc_column_text] \u2190 Back to Clinical&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/diaendo.com\/index.php\/study-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Diaendo\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-13T18:44:28+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/diaendo.com\\\/index.php\\\/study-4\\\/\",\"url\":\"https:\\\/\\\/diaendo.com\\\/index.php\\\/study-4\\\/\",\"name\":\"Eloralintide + Tirzepatide (Study 4) - Diaendo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/diaendo.com\\\/#website\"},\"datePublished\":\"2026-05-07T04:28:24+00:00\",\"dateModified\":\"2026-06-13T18:44:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/diaendo.com\\\/index.php\\\/study-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/diaendo.com\\\/index.php\\\/study-4\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/diaendo.com\\\/index.php\\\/study-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/diaendo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eloralintide + Tirzepatide (Study 4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/diaendo.com\\\/#website\",\"url\":\"https:\\\/\\\/diaendo.com\\\/\",\"name\":\"Diaendo\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/diaendo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/diaendo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/diaendo.com\\\/#organization\",\"name\":\"Diaendo\",\"url\":\"https:\\\/\\\/diaendo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/diaendo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/diaendo.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Logo-DES-Only-e1776570089619.jpg\",\"contentUrl\":\"https:\\\/\\\/diaendo.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Logo-DES-Only-e1776570089619.jpg\",\"width\":266,\"height\":228,\"caption\":\"Diaendo\"},\"image\":{\"@id\":\"https:\\\/\\\/diaendo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eloralintide + Tirzepatide (Study 4) - Diaendo","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Eloralintide + Tirzepatide (Study 4) - Diaendo","og_description":"[vc_row full_width=\u201dstretch_row\u201d css=\u201d.vc_custom_tt_hdr{background-color: #149d79 !important; padding-top: 28px !important; padding-bottom: 24px !important;}\u201d][vc_column][vc_custom_heading text=\u201dCurrently Recruiting \u00b7 Clinical Research\u201d font_container=\u201dtag:p|font_size:11px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dEloralintide + Tirzepatide in Overweight & Obesity\u201d font_container=\u201dtag:h1|font_size:36px|text_align:left|color:%23ffffff|line_height:1.15\u2033 use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dA study of LY3841136 (eloralintide), a GIP receptor agonist, given together with tirzepatide in adults who are overweight or have obesity.\u201d font_container=\u201dtag:p|font_size:15px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][\/vc_column][\/vc_row][vc_row][vc_column width=\u201d1\/1\u2033][vc_column_text] \u2190 Back to Clinical&hellip;","og_url":"https:\/\/diaendo.com\/index.php\/study-4\/","og_site_name":"Diaendo","article_modified_time":"2026-06-13T18:44:28+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/diaendo.com\/index.php\/study-4\/","url":"https:\/\/diaendo.com\/index.php\/study-4\/","name":"Eloralintide + Tirzepatide (Study 4) - Diaendo","isPartOf":{"@id":"https:\/\/diaendo.com\/#website"},"datePublished":"2026-05-07T04:28:24+00:00","dateModified":"2026-06-13T18:44:28+00:00","breadcrumb":{"@id":"https:\/\/diaendo.com\/index.php\/study-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/diaendo.com\/index.php\/study-4\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/diaendo.com\/index.php\/study-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/diaendo.com\/"},{"@type":"ListItem","position":2,"name":"Eloralintide + Tirzepatide (Study 4)"}]},{"@type":"WebSite","@id":"https:\/\/diaendo.com\/#website","url":"https:\/\/diaendo.com\/","name":"Diaendo","description":"","publisher":{"@id":"https:\/\/diaendo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/diaendo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/diaendo.com\/#organization","name":"Diaendo","url":"https:\/\/diaendo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/diaendo.com\/#\/schema\/logo\/image\/","url":"https:\/\/diaendo.com\/wp-content\/uploads\/2025\/04\/Logo-DES-Only-e1776570089619.jpg","contentUrl":"https:\/\/diaendo.com\/wp-content\/uploads\/2025\/04\/Logo-DES-Only-e1776570089619.jpg","width":266,"height":228,"caption":"Diaendo"},"image":{"@id":"https:\/\/diaendo.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/pages\/1022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/comments?post=1022"}],"version-history":[{"count":3,"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/pages\/1022\/revisions"}],"predecessor-version":[{"id":1230,"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/pages\/1022\/revisions\/1230"}],"wp:attachment":[{"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/media?parent=1022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}